🔴 GT Biopharma is trading 18.95% down today after $7.45 million private placement raises dilution concerns

GT Biopharma is trading 18.95% down at $6.58 as investors continue selling over dilution concerns tied to the September 15 announcement of a $7.45 million private placement involving convertible preferred stock and warrants.

• Financing includes conversion rights, warrants, and potential additional preferred issuance, creating substantial dilution concerns.
• Shares fell from $11.63 on September 14 to $7.81 on September 16, extending the post-financing selloff.
• The decline is occurring despite broader biotechnology strength; trading is volatile during the open, with price action sharply negative.